Summary
Biogen Inc. reported a net loss of $68.1 million for the third quarter of 2023, a significant change from the $1.13 billion net income in the same period last year. This shift was primarily driven by a substantial increase in total costs and expenses, particularly R&D and SG&A expenses, largely due to one-time costs associated with the acquisition of Reata Pharmaceuticals. Total revenue saw a slight increase of 0.9% to $2.53 billion, driven by growth in contract manufacturing and royalty revenue, which offset a 8.0% decline in product revenue. The decrease in product revenue was mainly attributed to ongoing generic competition for TECFIDERA and increased competition for TYSABRI, partially offset by growth in SPINRAZA. Operationally, the company completed the significant acquisition of Reata for approximately $7.2 billion, adding SKYCLARYS, a treatment for Friedreich's Ataxia, to its portfolio. This acquisition, while strategically important, significantly impacted the company's financial results for the quarter due to associated expenses. Management is also progressing with a 'Fit for Growth' program aimed at reducing operating costs by approximately $1.0 billion by 2025 through measures including headcount reductions. The company's cash position decreased significantly due to the Reata acquisition, but Biogen maintains adequate liquidity.
Financial Highlights
52 data points| Revenue | $2.53B |
| Cost of Revenue | $659.60M |
| Gross Profit | $1.87B |
| SG&A Expenses | $788.20M |
| Operating Expenses | $2.67B |
| Interest Expense | $63.80M |
| Net Income | -$68.10M |
| EPS (Basic) | $-0.47 |
| EPS (Diluted) | $-0.47 |
| Shares Outstanding (Basic) | 144.80M |
| Shares Outstanding (Diluted) | 144.80M |
Key Highlights
- 1Biogen reported a net loss of $68.1 million for Q3 2023, compared to a net income of $1.13 billion in Q3 2022.
- 2Total revenue for Q3 2023 increased slightly by 0.9% to $2.53 billion, driven by contract manufacturing and royalty revenue, offsetting an 8.0% decrease in product revenue.
- 3Product revenue declined primarily due to generic competition for TECFIDERA and increased competition for TYSABRI, while SPINRAZA showed modest growth.
- 4The company completed the acquisition of Reata Pharmaceuticals for approximately $7.2 billion, a major strategic move that significantly impacted the quarter's expenses.
- 5Total costs and expenses increased by 134.9% to $2.67 billion, largely due to acquisition-related expenses and increased R&D and SG&A spending.
- 6Biogen is implementing a 'Fit for Growth' program targeting $1.0 billion in gross operating expense savings by 2025, including workforce reductions.
- 7Cash, cash equivalents, and marketable securities decreased to $2.3 billion as of September 30, 2023, primarily due to funds used for the Reata acquisition.